Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m7sBK6b
via IFTTT

Read More

Medical devices industry needs to focus more on local value addition: Pharma Secy

The medical devices sector must increase local value addition and component manufacturing. Government officials are open to industry suggestions for PLI scheme beneficiaries. Many companies invested but could not claim incentives for various reasons. The government aims to incentivize component makers more than assembly operations. Increased domestic value addition is a key objective for the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5IK8kP
via IFTTT

Read More

Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta

The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptively similar to Dr Reddy's Labs' Daplo trademark. Both trademarks are used for prescription drugs treating Type-2 diabetes Mellitus. The court cited phonetic similarity and potential consumer confusion as key reasons. Razenta's trademark registration was cancelled within six weeks by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBO9zsi
via IFTTT

Read More

Lupin arm to commercialise YUVEZZI eye drop across key European markets

Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bm03Nq4
via IFTTT

Read More

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p51oUgc
via IFTTT

Read More

Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences

Pharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficient resource utilisation and greater economies of scale. The merger will improve operating parameters and maximise shareholder value through integration. Greater efficiency in cash management and access to cash flows is also expected. Business processes will be simplified, reducing administrative expenses and compliance costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CBf5Zeo
via IFTTT

Read More

Lord’s Mark Industries announces license for biomescan analytics platform

Lord's Mark Industries has obtained a license for its groundbreaking Biomescan Analytics Platform, which specializes in assessing the gut microbiome to deliver customized health insights. With ambitious plans to set up 3,000 health centers across India in the next three years, the initiative aims to offer gut assessments and personalized nutritional advice, promoting proactive health and enhancing long-term wellness outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xolc8ZJ
via IFTTT

Read More

Apollo Hospitals extends services to all seven days of week

Apollo Hospitals will now offer routine healthcare services on Sundays. This initiative extends outpatient consultations and diagnostic services to weekends. Scheduled procedures and follow-up care will also be available, complementing existing emergency services. The hospital group aims to improve access for busy professionals and families. This move reinforces Apollo's commitment to preventive and timely medical care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BYSO56a
via IFTTT

Read More

Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru

Manipal Health Enterprises will acquire Kinder Women's Hospital in Bengaluru for Rs 130 crore. This business transfer agreement involves acquiring the hospital's entire operations and assets. The acquisition strengthens Manipal Hospitals' position in a growing Bengaluru healthcare market. It will also expand access to their clinical expertise and capabilities for more patients. This move complements their existing healthcare ecosystem in the Whitefield micro-market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YGcSIrw
via IFTTT

Read More

Healthcare delivery capital-intensive, hospital tariffs only tip of iceberg: NATHEALTH

Healthcare delivery costs are capital-intensive and investment-heavy, according to NATHEALTH. Policy discussions should address structural costs like land and manpower. Hospitals require continuous investment in infrastructure and specialized equipment. The industry warns against regulatory changes that deter expansion and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2IDifRN
via IFTTT

Read More

India's pharma sector must shift from cost competitiveness to innovation, global quality: Experts

For the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that increasing investments in research and digital technologies could propel the market to an impressive USD 130 billion by 2030. Companies must also elevate their quality and comply with global regulatory expectations to compete in the global landscape, thus establishing India as an innovation hub in life sciences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ILvMO8R
via IFTTT

Read More

Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness

Pharma major Lupin Ltd announced receiving final USFDA approval for its generic Pitolisant tablets. These tablets are indicated for treating excessive daytime sleepiness in patients. The US health regulator approved strengths of 4.45 mg and 17.8 mg. Lupin's Pitolisant tablets are bioequivalent to Wakix, a prescription medicine. This approval marks a significant step for the company in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EmgD0VJ
via IFTTT

Read More

Aurobindo Pharma’s Raleigh plant gets 'Voluntary Action Indicated' classification from US FDA

Aurobindo Pharma's US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufacturing plant. This classification allows applications for inhalers and other products to proceed. The inspection covered inhaler, dermatology, and transdermal product manufacturing operations. The company's regulatory filing confirmed the inspection closure and VAI status.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Vnv42K
via IFTTT

Read More

India plans national sports medicine framework ahead of 2036 Olympics

India plans a national sports medicine framework for preventive athlete care. This initiative aims to standardize injury protocols and link medical institutions. The government considers a phased rollout by 2028 for this new system. This framework will improve athlete availability and long-term career sustainability. The proposal supports India's potential 2036 Olympic Games bid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7stunQp
via IFTTT

Read More

In private healthcare's rise, price points are a big pain

In a recent proposal, a parliamentary committee has recommended that hospital room charges not exceed the rates of three-star hotels. The substantial growth of private healthcare as an industry has attracted considerable private equity investment, resulting in valuation spikes and shifts in ownership among hospital chains. However, this raises important questions about the accessibility of healthcare for the average person.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UQe6Rc9
via IFTTT

Read More

AI could cut doctors' paperwork burden as global health worker shortage looms: Report

Artificial intelligence can ease doctor workloads by handling repetitive administrative tasks. This technology helps address a growing global healthcare worker shortage. AI tools can draft clinical documentation, freeing up valuable physician time. Patients can also benefit as AI helps direct them to appropriate care. Ultimately, AI aims to optimize existing healthcare staff for future demands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ci0UH8Y
via IFTTT

Read More

Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovation

Thermo Fisher Scientific is amplifying its investment footprint in India, driven by the strong anticipated growth in the biosimilars and innovative medicines sectors. With projections indicating a substantial rise in India's biosimilars exports by 2030, local pharmaceutical companies are pivoting towards advanced biologics and research initiatives. To foster scientific talent, Thermo Fisher has also established a bioprocess center in Hyderabad for comprehensive training.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TPJej1A
via IFTTT

Read More

Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA

Aurobindo Pharma announced its subsidiary Eugia Pharma received a USFDA warning letter. This follows an inspection of their Telangana formulation manufacturing facility. The inspection concluded with four observations and an official action indicated status. The company stated existing US market supplies remain unaffected by this development. Aurobindo Pharma continues its commitment to ongoing compliance with the US FDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ftbaj2p
via IFTTT

Read More

Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEO

Gland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to his acceptance of the offer. Sapra brings 27 years of executive experience, including over 23 years in pharmaceuticals, and currently leads API and Services at Dr Reddy’s Laboratories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5hNoz4M
via IFTTT

Read More

Delhi HC backs Zydus in trademark row

The Delhi High Court upheld a single-judge order against Alder Biochem. This ruling prevents them from using the 'Biochem' trademark. Alder Biochem's claim of the term being public property was rejected. Zydus Healthcare has held the registered trademark since 1959. The court's decision protects Zydus Healthcare's established brand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gW8LpqF
via IFTTT

Read More

Narayana Health, NDB sign pact to share smart hospital expertise

Narayana Health and the New Development Bank have signed a knowledge-sharing agreement. This partnership aims to strengthen smart hospital capabilities and patient-centric healthcare services. The collaboration will focus on digital health and technology transfer for emerging economies. NDB president Dilma Rousseff and Narayana Health chairman Dr Devi Shetty signed the memorandum. This initiative supports NDB's mission to finance development projects in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6KRl4BX
via IFTTT

Read More

Govt tightens drug quality net, initiates 950 actions since 2022: Over 1,100 cough syrup makers are also facing intensive audits amid quality concerns

The government has initiated 950 enforcement actions against pharmaceutical companies since December 2022. These actions aim to improve the quality of locally made medicines and prevent spurious drug sales. More than 1,100 cough syrup manufacturers are facing intense audits due to quality concerns. Drug manufacturing premises are inspected periodically to verify compliance with good manufacturing practices. Risk-based inspections are now prioritized based on a company's risk profile.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gSt4ryk
via IFTTT

Read More

Maharashtra FDA cracks down on Ayurvedic drug makers, cancels 10 licences

Maharashtra FDA has launched a statewide crackdown on Ayurvedic drug manufacturers. Inspections revealed serious violations of manufacturing and quality control standards at many establishments. Following these findings, 135 manufacturers received show-cause notices for non-compliance issues. Ten manufacturers had their licenses permanently cancelled due to major violations affecting public health. The FDA is ensuring Ayurvedic medicines meet required standards and addressing public health lapses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DpL0RfQ
via IFTTT

Read More

Regulator mandates full review of globally unapproved drugs

India’s drug regulator has clarified that new drugs not approved anywhere globally must undergo the full domestic regulatory process, even if Indian patients participated in global clinical trials. CDSCO said such applications require comprehensive safety and efficacy evaluation under existing rules.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7GwBYO
via IFTTT

Read More

US-based Amgen to open science and innovation center at Genome Valley in Hyderabad

Amgen will open a new science and innovation center in Hyderabad's Genome Valley. This facility is expected to become operational by the year 2027. The center will integrate experimental science with data and technology. It will expand Amgen's global research and development capabilities significantly. This investment highlights Hyderabad's growing importance as a global research hub.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nrjhl6a
via IFTTT

Read More

Philips India sees India emerging as global R&D, AI hub; bets on healthcare infrastructure for growth

Philips India is focusing on growing healthcare infrastructure and artificial intelligence. The company's R&D footprint in India is significantly strengthening its global operations. Investments will continue to support Philips' positive growth story in the country. Philips sees opportunities in sleep and respiratory care as awareness increases. The company prioritizes value over price when facing competition from other firms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sVzXPZ0
via IFTTT

Read More

Doctors' safety alert led to Sun Pharma eye drop recall

Sun Pharma recalled eleven eyecare products after an eye specialists' body issued a safety alert. This alert warned about bacterial contamination found in certain batches of their Predmet eyedrop medicine. The All India Ophthalmological Society stressed patient safety due to potential serious ocular infection risks. Sun Pharma stated the recall was a precautionary measure while investigations continued. The company assured that other products were manufactured at different qualified sites.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZuyJwrL
via IFTTT

Read More

Medical devices are not pharma products, companies say while opposing Draft Bill

India’s medical device industry and healthcare groups have opposed the draft Drugs, Medical Devices and Cosmetics Bill, 2026, arguing that treating medical devices like pharmaceuticals and imposing criminal penalties for regulatory lapses could hurt manufacturing, investment and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1GpvPLc
via IFTTT

Read More

Wockhardt takes on India’s superbug crisis with new antibiotic academy

Wockhardt has launched the Antibiotic Academy, an open scientific learning platform to strengthen clinical dialogue and evidence-based management of antimicrobial resistance in India. The initiative will connect clinicians, experts, hospitals, scientific societies and policymakers to promote appropriate antibiotic use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0aSxlTn
via IFTTT

Read More

Warburg set to buy Seacod-maker Universal NutriScience for Rs 2800 crore

Will be 4th acquisition for the US private equity giant in India’s healthsector in four months. Kedaara to make 5x rupee returns on exit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MZxPlOS
via IFTTT

Read More

Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenue

Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer, manufacturing and supply of sterile injectable products. The agreement covers 55 SKUs across three sites, with annualised revenue potential of $90-100 million upon commercialisation. Revenue generation is expected to begin in 2029.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aBfGJPW
via IFTTT

Read More

IIT Guwahati develops 'E-Eye' for rapid detection of Cancer-causing heavy metals and other toxicants

IIT Guwahati researchers have developed an innovative optical sensing device for detecting water toxicants. This portable E-Eye device offers instant and accurate on-site analysis of various contaminants. It works by converting chemical reactions into digital data for easy interpretation. The technology aligns with the Jal Jeevan Mission, aiming to ensure safe drinking water for all. This innovation holds significant potential for government, industry, and public health applications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LCGKXBI
via IFTTT

Read More

Govt plans new drugs law to overhaul pharma, medical device regulation

The government is set to replace the 1940 Drugs and Cosmetics Act with a new law covering drugs, medical devices and cosmetics. The draft bill strengthens the powers of the DCGI, introduces stricter bail provisions for serious drug offences, enables faster approvals and recalls, and creates dedicated regulatory and advisory bodies for medical devices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oAaKHfU
via IFTTT

Read More

Emcure Pharma net profit up 36% at Rs 292 crore

Emcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivity gains. Net profit saw a significant 36.2% rise during the period. The company began its five-year plan on a strong footing for FY27. Emcure also completed the acquisition of a minority stake in Gennova Biopharmaceuticals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6Lxt2Mk
via IFTTT

Read More

KKR deepens India healthcare bet with $1.39 billion Medicover acquisition

Global investment firm KKR has acquired Medicover India's hospital network for $1.39 billion. This acquisition marks KKR's third hospital purchase in recent years. Medicover India operates 24 multi-specialty hospitals across South and West India. The European healthcare chain will now focus its operations solely within the continent. This transaction allows Medicover to strengthen its financial position and pursue European growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0zUcEjF
via IFTTT

Read More

Centre to bar drugmakers from selling mislabelled, fraudulently approved products under new provisions

New rules will bar drugmakers from selling products if false information was provided. The Union Ministry of Health & Family Welfare has amended the Drugs Rules, 1945. This adds accountability for drug manufacturers and distributors operating in the country. The Licensing Authority can now debar entities from filing future applications. This amendment aims to deter misconduct and ensure reliable drug approval evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B15tvuK
via IFTTT

Read More

KKR buys Medicover’s India hospitals business

Global investment firm KKR has acquired Medicover India's hospital business. Sources said the the transaction values the hospital chain at around ₹10,000 crore and KKR may invest another ₹3,000-4,000 crore to fuel expansion. The acquisition strengthens KKR's healthcare portfolio, adding Medicover's 24-hospital network while reinforcing its long-term strategy to capitalise on India's rapidly growing healthcare and hospital sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7foyniQ
via IFTTT

Read More

KKR to acquire Medicover India in $1.5 billion deal

The transaction includes a sale of 100% stake by existing shareholders, as well as a commitment to deploy fresh capital to fund its growth and repay debt. In all, KKR will be spending Rs 13,000-14,000 crore, around quarter of which (Rs 3,000-4,000 crore) will go into the company as primary capital, said people aware of developments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7YfatJ9
via IFTTT

Read More

Delhi HC seeks response on Natco's patent challenge plea

The Delhi High Court is reviewing Natco Pharma's challenge to a breast cancer drug patent. Natco alleges Novartis and Astex secured two patents for the same invention. This action, Natco claims, unlawfully extends patent protection for the Ribociclib molecule. The court will first determine the petition's maintainability after legal arguments. The case has been scheduled for further hearing on September 16.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m8p3J7K
via IFTTT

Read More

Cipla, Rocket India announce Rs 300 crore expansion plans in Karnataka; Blackstone eyes data centres

Cipla and Rocket India will invest Rs 300 crore in Karnataka's manufacturing facilities. Blackstone is exploring investments in data centers and renewable energy infrastructure. Saint-Gobain plans to expand its manufacturing footprint within the state. Horizon is encouraged to consider industrial projects in tier two cities. These announcements occurred during Karnataka's investment roadshow in Mumbai.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W46dIZb
via IFTTT

Read More

IPA seeks to regularise 'legacy' drugs

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examples include sodium valproate and carbamazepine tablets. Regulatory gaps have persisted for over a decade. This situation requires urgent attention from drug authorities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vClqPwm
via IFTTT

Read More

Dr Reddy's Laboratories launches generic Sugammadex injection in the United States

Dr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effects given during surgical procedures. The company's hospital portfolio expands with this important medicine's availability. Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global network. This launch occurred on the first day of generic availability in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SiFyJOU
via IFTTT

Read More

India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncertainty and Middle East shipping disruptions hurt exports, Pharmaceuticals Export Promotion Council of India Chairman Namit Joshi told Reuters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/867Jmlf
via IFTTT

Read More

Private equity firm Creador in talks to buy into generic drug co Leeford Health

Private equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kf5xhTv
via IFTTT

Read More

Two-wheeled road ambulance to run from October 1, 2027

The Centre has proposed introducing a regulatory framework for two-wheeled road ambulances, which will become operational from October 1, 2027, to improve emergency medical access in rural, remote and hilly areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKeP0ZV
via IFTTT

Read More

Losing weight fast on GLP-1 drugs? Your hair could be the next thing to go

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen effluvium, stems from nutritional deficiencies and metabolic stress. Many patients start these medications without proper medical supervision, influenced by social media trends. Studies show a high prevalence of hair shedding, particularly among women and significant weight losers. Doctors advise medical supervision and balanced nutrition to manage this temporary condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSpeEKr
via IFTTT

Read More

India's Second Leapfrog: From sick-care to AI-native health infrastructure

Just as India bypassed copper landlines to become a global mobile data leader, it can now bypass the West's CPT-coded sick-care bureaucracy and build AI-powered, personalised healthspan infrastructure for the world.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VWaiTPn
via IFTTT

Read More

GLP-1 demand stirs up hunger for obesity care talent

Demand for nutrition professionals is rapidly increasing across India. Hospitals and digital health platforms are hiring more dietitians and educators. This trend supports patients using new GLP-1 obesity medications. Specialized obesity care teams are expanding to meet growing patient needs. Long-term monitoring and lifestyle support are crucial for sustained health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7SEy0he
via IFTTT

Read More

Jackson Labs' Baddi drug manufacturing licence restored after suspension

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/agUXoKF
via IFTTT

Read More

Sun Pharma recalls eye drops in India after contamination scare

"Withdrawal of Product - Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F & Nepalact E/D 5ML."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I9GNHCo
via IFTTT

Read More